Skip to main content

Table 1 Distribution of baseline variables by concurrent ADT status

From: The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation

Variable

ADT

No ADT

Total

p-value

no ADT

p-value

 

(cases)

(unmatched controls)

 

(unmatched)

(matched controls)

(matched)

 

n = 421

n = 797

n = 1218

 

n = 421

 

Mean age

68.63

68.5

 

0.75

68.4

0.67

Mean PSA

8.47

8.18

 

0.28

8.12

0.252

Gleason Score (mean)

6.9

6.38

 

<0.001

6.83

0.99

Race

   

<0.001

 

0.042

White

278 (11.7%)

650 (81.6)

928

 

313 (74.3%)

 

Black

79 (18.8%)

96 (12%)

175

 

67 (15.9%)

 

Hispanic

44 (10.4%)

34 (4.3%)

78

 

27 (6.4%)

 

Other

20 (4.8%)

17 (2.1%)

37

 

14 (3.3%)

 

Year of diagnosis (mean)

2003

1997

 

<0.001

2001

<0.001

Dose of radiation

   

<0.001

  

Low ≤ 70

28 (6.6%)

390 (49.8%)

418

 

71 (16.9%)

<0.001

High > 70

393 (93.3%)

407 (51.1%)

800

 

350 (8.3%)

 

Clinical T-stage

   

0.27

 

0.47

T1

205 (48.7%)

336 (42.2%)

571

 

234 (55.6%)

 

T2a

94 (22.3%)

164 (20.1%)

258

 

95 (22.6%)

 

T2b,c

122 (30%)

267 (33.5%)

389

 

92 (21.8%)

 

Length of concurrent hormones*

      

Short (≤6 months)

271 (64.4%)

 

271

   

Long (>6 months)

150 (35.6%)

 

150

   

Timing of hormones

      

Neoadjuvant

371 (88.1%)

 

371

   

Adjuvant

50 (11.9%)

 

50

   

Salvage

8 (1.9%)

114 (14.3%)

122

<0.001

40 (9.5%)

<0.001

Radiation type<

     

<0.001

3-D conformal

73 (17.3%)

546 (68.5%)

619

<0.001

171 (40.6%)

 

IMRT

348 (82.7%)

251 (31.5%)

599

 

250 (59.4%)

 
  1. *(of patients who received adjuvant hormones).
  2. Percentages may not sum to 100% due to rounding.